Thursday 16 October, 2025
Objectives: To quantify the relationship between exposure to lacosamide (LCM) and seizure probability in monotherapy and to explore the relationship with…
Read morePoster: Drug/Disease modeling - CNS
Modelling of Pharmacokinetics and the Incidence of Adverse Events of the PDE-10A Inhibitor TAK-063
Thursday 16 October, 2025
Objectives: TAK-063 is a potent and selective inhibitor of the phosphodiesterase 10A enzyme expressed primarily in the striatal medium spiny…
Read moreAmyloid related imaging abnormalities (ARIA): Time to event modeling to identify new Phase 3 doses and dosing regimens for Gantenerumab
Thursday 16 October, 2025
Objectives: SCarlet RoAD (SR) was set up as a pivotal Phase 3 study to evaluate the effect of 105 and…
Read morePopulation PK modeling and simulation to support dose selection of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenic patients.
Thursday 16 October, 2025
Objectives: RBP-7000 is a sustained-release formulation of risperidone being currently developed for the treatment of schizophrenia. RBP-7000 has been designed…
Read morePopulation Pharmacokinetic (PK) Modelling of Ketamine and Norketamine in Plasma, Prefrontal Cortex (PFC) and Cerebrospinal Fluid (CSF) after Subcutaneous (SC) Administration of S(+)-Ketamine in Rats.
Thursday 16 October, 2025
Objectives: The goal of the current analysis is to develop a semi-physiologically based PK model for S(+)-Ketamine (S-Ket) in rats…
Read moreModel-based meta-analysis of amyloid plaque reduction in Alzheimer’s disease patients to identify new Phase 3 doses and dosing regimens for Gantenerumab
Thursday 16 October, 2025
Objectives: A pre-specified futility analysis of SCarlet RoAD (SR), a Phase 3 of the anti-Aβ antibody gantenerumab (GAN) in prodromal…
Read moreItem response theory for analyzing placebo and drug treatment in Phase 3 studies of schizophrenia
Thursday 16 October, 2025
Objectives: In schizophrenia, the effects of placebo and drug treatment are often quantified using total PANSS scores. Treatment effects on…
Read morePopulation Pharmacokinetic Simulations of Two Paliperidone Palmitate Formulations
Thursday 16 October, 2025
Background: Population pharmacokinetic (PK) models have been developed for paliperidone palmitate 1 and 3-month formulations (PP1M and PP3M). Objective: To investigate dosing…
Read morePopulation pharmacokinetic/pharmacodynamic modelling of the analgesic and pupillometry effects of axomadol and its O-demethyl metabolite in healthy subjects
Thursday 16 October, 2025
Objectives: To characterize the PKPD properties of the active components of axomadol (GRT0151Y) quantifying their contribution to the analgesic and…
Read moreMarkov Model for Lithium Compliance Assessment
Thursday 16 October, 2025
Introduction: Lithium is an antidepressant used as primary treatment for the prevention of episode recurrences in bipolar disorder, acute treatment of…
Read more